A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

This early-phase study is testing a new drug called RNDO-564, either alone or combined with pembrolizumab (an immunotherapy), in people with advanced cancers including bladder cancer, lung cancer, head and neck cancer, cervical cancer, stomach cancer, esophageal cancer, and triple-negative breast cancer. These are cancers with a specific protein (called Nectin-4) that the drug targets. **You may be eligible if...** - You have advanced or metastatic bladder (urothelial) cancer, squamous cell lung cancer, head and neck cancer, cervical cancer, gastric cancer, esophageal cancer, or triple-negative breast cancer - Your cancer has continued to grow despite standard treatments - You are well enough to tolerate cancer therapy **You may NOT be eligible if...** - You have untreated or uncontrolled cancer that has spread to the brain - You have significant nerve damage (peripheral neuropathy) above Grade 2 - You have had certain prior treatments that may interfere - You have serious heart, lung, liver, or kidney conditions Talk to your doctor to see if this trial is right for you.